Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis ; volume:37 ; number:3 ; day:23 ; month:3 ; year:2023 ; pages:409-420 ; date:5.2023
BioDrugs ; 37, Heft 3 (23.3.2023), 409-420, 5.2023
- Klassifikation
-
Wirtschaft
- Urheber
-
Peng, Kuan
Blais, Joseph E.
Pratt, Nicole L.
Guo, Jeff Jianfei
Hillen, Jodie B.
Stanford, Tyman
Ward, Michael
Lai, Edward Chia-Cheng
Shin, Ju-Young
Tong, Xinning
Fan, Min
Cheng, Franco W. T.
Wu, Jing
Yeung, Winnie W. Y.
Lau, Chak-Sing
Leung, Wai Keung
Wong, Ian C. K.
Li, Xue
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-023-00589-3
- URN
-
urn:nbn:de:101:1-2023090910320583233281
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peng, Kuan
- Blais, Joseph E.
- Pratt, Nicole L.
- Guo, Jeff Jianfei
- Hillen, Jodie B.
- Stanford, Tyman
- Ward, Michael
- Lai, Edward Chia-Cheng
- Shin, Ju-Young
- Tong, Xinning
- Fan, Min
- Cheng, Franco W. T.
- Wu, Jing
- Yeung, Winnie W. Y.
- Lau, Chak-Sing
- Leung, Wai Keung
- Wong, Ian C. K.
- Li, Xue
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar